This creates a gap where private insurance patients get discounts, but Medicaid patients don't qualify
The effects of GLP-1RAs on pancreatic cancer risk The relationship between GLP-1RA administration and pancreatic cancer risk remains a subject of significant debate in contemporary research
Figure 1B shows the natural abundance of HDO in the mouse brain before injection of [6,6]- 2 H 2 glucose, which was used as an internal concentration reference
GLP-1 medications cause nausea, vomiting, diarrhea, and constipation in a substantial percentage of patients, especially during dose titration
So when a drug goes under shortage, that essentially gives authority to these compounders to start producing them, you know, to fill in these access gaps